Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization

Area of Science:

• Pharmacology
• Neuroscience
• Immunology

Background:

• Naltrexone and naloxone are classical opioid antagonists with distinct pharmacodynamics at lower doses.
• Low-dose naltrexone (LDN), very low-dose naltrexone (VLDN), and ultra low-dose naltrexone/naloxone (ULDN) represent novel therapeutic approaches.
• These low doses have been scarcely evaluated scientifically despite emerging clinical reports.

Purpose of the Study:

• To review the current knowledge on the pharmacodynamics and potential applications of low-dose naltrexone and naloxone.
• To summarize key findings from peer-reviewed sources regarding LDN, VLDN, and ULDN.
• To highlight the unexplored potential of these low-dose opioid antagonists in biomedicine.

Main Methods:

• Literature review of peer-reviewed scientific publications.
• Analysis of studies investigating low-dose naltrexone (1-5 mg daily) effects on glial inflammatory response and opioid signaling.
• Examination of research on ultra low-dose naltrexone/naloxone (<1 μg daily) in potentiating analgesia and very low-dose naltrexone (1 μg-1 mg) in opioid-weaning.

Main Results:

• Low-dose naltrexone (LDN) modulates Toll-like receptor 4 signaling, reducing glial inflammation and upregulating endogenous opioid signaling.
• Ultra low-dose naltrexone/naloxone (ULDN) potentiates opioid analgesia and reduces opioid requirements post-surgery.
• Very low-dose naltrexone (VLDN) has been explored as an adjunct for methadone taper.

Conclusions:

• Low-dose formulations of naltrexone and naloxone exhibit unique pharmacological effects distinct from standard doses.
• Clinical reports suggest potential benefits in conditions like fibromyalgia, Crohn's disease, and multiple sclerosis.
• The full therapeutic potential of LDN, VLDN, and ULDN requires comprehensive scientific investigation.